Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Mar 27;123(13):2017-25.
doi: 10.1182/blood-2013-10-534297. Epub 2014 Feb 4.

The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial

Michael A Pulsipher  1 , Bryan Langholz, Donna A Wall, Kirk R Schultz, Nancy Bunin, William L Carroll, Elizabeth Raetz, Sharon Gardner, Julie M Gastier-Foster, Denise Howrie, Rakesh K Goyal, James G Douglas, Michael Borowitz, Yvonne Barnes, David T Teachey, Candace Taylor, Stephan A Grupp
Affiliations
Clinical Trial

The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial

Michael A Pulsipher et al. Blood. .

Abstract

Sirolimus has activity against acute lymphoblastic leukemia (ALL) in xenograft models and efficacy in preventing acute graft-versus-host disease (aGVHD). We tested whether addition of sirolimus to GVHD prophylaxis of children with ALL would decrease aGVHD and relapse. Patients were randomized to tacrolimus/methotrexate (standard) or tacrolimus/methotrexate/sirolimus (experimental). The study met futility rules for survival after enrolling 146 of 259 patients. Rate of Grade 2-4 aGVHD was 31% vs 18% (standard vs experimental, P = .04), however, grade 3-4 aGVHD was not different (13% vs 10%, P = .28). Rates of veno-occlusive disease (VOD) and thrombotic microangiopathy (TMA) were lower in the nonsirolimus arm (9% vs 21% VOD, P = .05; 1% vs 10% TMA, P = .06). At 2 years, event free survival (EFS) and overall survival (OS) were 56% vs 46%, and 65% vs 55% (standard vs experimental), respectively (P = .28 and .23). Multivariate analysis showed increased relapse risk in children with ≥0.1% minimal residual disease (MRD) pretransplant, and decreased risk in patients with grades 1-3 aGVHD (P = .04). Grades 1-3 aGVHD were associated with improved EFS (P = .02), whereas grade 4 aGVHD and extramedullary disease at diagnosis led to inferior OS. Although addition of sirolimus decreased aGVHD, survival was not improved. This study is registered with ClinicalTrials.gov as #NCT00382109.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Consort diagram. Flow of patients enrolled on the trial.
Figure 2
Figure 2
Survival outcomes. (A) EFS by treatment arm. (B) OS by treatment arm. (C) EFS by risk category. (D) EFS by subgroups of very high-risk CR1 patients.
Figure 3
Figure 3
The effect of aGVHD and MRD on relapse and survival. (A) Relapse probability curves for patients with grade 1-3 aGVHD by day 55 and with no aGVHD by day 55. (B) EFS probability by aGVHD status and treatment arm. (C) Relapse probability by pre-HCT MRD status.
See this image and copyright information in PMC

References

    1. Eapen M, Raetz E, Zhang MJ, et al. Children’s Oncology Group; Center for International Blood and Marrow Transplant Research. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children’s Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood. 2006;107(12):4961–4967. - PMC - PubMed
    1. Borgmann A, von Stackelberg A, Hartmann R, et al. Berlin-Frankfurt-Münster Relapse Study Group. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. Blood. 2003;101(10):3835–3839. - PubMed
    1. Oliansky DM, Camitta B, Gaynon P, et al. Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review [published correction appears in Biol Blood Marrow Transplant. 2012;18(9):1466]. Biol Blood Marrow Transplant. 2012. 18(4):505-522. - PubMed
    1. MacMillan ML, Davies SM, Nelson GO, et al. Twenty years of unrelated donor bone marrow transplantation for pediatric acute leukemia facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant. 2008;14(suppl 9):16–22. - PubMed
    1. Harvey J, Green A, Cornish J, et al. Improved survival in matched unrelated donor transplant for childhood ALL since the introduction of high-resolution matching at HLA class I and II. Bone Marrow Transplant. 2012;47(10):1294–1300. - PubMed

Publication types

Associated data